ImmunityBio shares surged as much as 14% on Wednesday, reaching their highest level in nearly seven weeks while lifting ...

ImmunityBio shares were up 14% to $3.52 after the company entered into a collaboration and supply agreement with BeiGene. The two companies will conduct a confirmatory randomized Phase 3 clinical ...

Starbucks Corporation SBUX gained 5.7% to $106.15 following better-than-expected quarterly financial results. Additionally, ...

REPAY , a leading provider of vertically-integrated payment solutions, today announced a strategic integration with Worth, the all-in-one fintech platform for underwriting and onboarding workflow ...

SolarBank Corporation (Cboe CA: SUNN) ("SolarBank" or the "Company") today announces highlights and new milestones reached during the 2024 calendar year.  The company remains committed to pioneering ...

The owner of the Los Angeles Times discusses his fight to cure cancer and why he wants President Donald Trump to succeed in ...

ImmunityBio (IBRX) announced the European Medicines Agency has accepted for review and begun assessing the marketing authorization application ...

The FDA approved a wide range of therapies in 2024, including many new molecular entities and biological products.

2025 is set to be a game-changing year for cancer research, with cutting-edge therapies and technologies driving unprecedented progress in oncology.

ImmunityBio has a promising cancer treatment, Anktiva. We warn of financial risks and lack of transparency for retail investors. See more on IBRX stock here.

We recently compiled a list of the 12 Stocks Under $5 With Biggest Upside Potential. In this article, we are going to take a ...

ImmunityBio, Inc. (NASDAQ:IBRX) saw a surge in its share prices last week, closing higher by 21.49 percent at $2.94 apiece as ...